

For immediate release




MILabs advances multimodality cardiac imaging with new installation at Yale

UTRECHT, THE NETHERLANDS, August 8, 2016

MILabs will provide an advanced U-SPECT⁴CT system to the Yale Translational Research Imaging Center (Y-TRIC) in New Haven-Connecticut, with support of an NIH Shared Instrument Grant for advancing their program in multimodality molecular and translational cardiovascular imaging research.

The MILabs U-SPECT⁴CT acquired by **Y-TRIC** is designed to address a broad range of non-invasive imaging research in animals, from imaging probe and translational applications development to performing multimodality anatomic, physiological, and molecular imaging, plus image registration and quantification. Yale will use the new MILabs system for targeted molecular imaging and the assessment of regional myocardial perfusion, function and metabolism in investigational studies in small animals.



High-resolution U-SPECT⁴CT image of a mouse model of human coronary heart disease.

Dr. Albert Sinusas, Professor of Medicine and Director Cardiovascular Imaging and Director of the Translational Research Imaging Center at Yale University expects utilizing the high-quality gated SPECT and CT functions of the U-SPECT/CT system to expand his cardiac research to areas inaccessible with other systems. Professor Sinusas, recipient of the prestigious 2008 Hermann Blumgart Award, explains: “We expect that this new hybrid imaging system will enable our laboratory to advance our effort on targeted molecular imaging and the development of non-invasive nuclear imaging strategies to study the biological processes (i.e. inflammation, angiogenesis, arteriogenesis) associated with atherosclerosis, peripheral artery disease, ischemic heart disease, and post-infarct remodeling”.

“With the recent addition of Adaptive X-ray CT modality with dual respiratory and cardiac gating to our fourth-generation ultra-high resolution U-SPECT platform, we have further enhanced the quantification capabilities of hybrid cardiac SPECT/CT, especially for molecularly targeted radiotracer uptake” explains Dr. F. Beekman, Founder and CEO of MILabs.

MILabs B.V. (Utrecht, the Netherlands) provides high-end molecular imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. As documented in over hundreds of scientific articles, U-SPECT provides the fastest, most sensitive and highest resolution small-animal SPECT system currently available. Recently MILabs fused state-of-the-art Adaptive PET with its SPECT technology by introducing VECTor/CT. This versatile nuclear imaging system is an extremely powerful non-invasive imaging system for small animals since it enables simultaneous sub-mm resolution PET/SPECT acquisitions of co-injected PET and SPECT tracers. Moreover, the VECTor platform offers the extreme flexibility of accommodating additional high-resolution, low-dose X-ray CT and Hybrid Optical luminescence and fluorescence imaging capabilities. For more information, visit www.milabs.com